Author:
Chen Mengjie,Pu Lihui,Gan Yuqin,Wang Xiaoxia,Kong Laixi,Guo Maoting,Yang Huiqi,Li Zhe,Xiong Zhenzhen
Abstract
AbstractThe variability in diabetes risk factors, such as uric acid and lipids, may influence the development of complications. This study aimed to investigate the influence of such variability on the occurrence of diabetic complications. A retrospective analysis of electronic medical records was conducted with type 2 diabetic patients who received treatment at a tertiary care hospital in Chengdu, Sichuan Province, between 2013 and 2022. The risk factor variability is presented as the standard deviation (SD). The associations between the variability and complications were examined using a binary logistic regression model. The study included 369 patients with type 2 diabetes. The findings revealed that outpatient special disease management served as a protective factor against the development of complications [OR = 0.53, 95% confidence interval (CI) (0.29–0.10)], particularly for the prevention of diabetic peripheral neuropathy [OR = 0.51, 95% CI (0.30–0.86)]. Variability in total cholesterol (TC-SD) was found to be a risk factor for the development of complications [OR = 2.42, 95% CI (1.18–4.97)] and acted as a risk factor for diabetic peripheral vasculopathy [OR = 2.50, 95% CI (1.25–5.02)]. TC-SD is a risk factor for the occurrence of diabetic peripheral neuropathy and diabetic peripheral vasculopathy, whereas outpatient special disease management functions as a protective factor against complications and diabetic peripheral neuropathy. Thus, in addition to glycaemic control, the regulation of lipid levels should be emphasized, particularly among patients without outpatient special disease management, to delay the onset of complications.
Funder
the 2022 Clinical Medicine Research Center for Geriatric Diseases Open Topics
Publisher
Springer Science and Business Media LLC
Reference67 articles.
1. Bo, Z. & Wenying, Y. Outlook for the epidemiology and prevention of diabetes in China. Chin. J. Diab. 11(1), 7–10 (2019).
2. Chinese, M. A. D. B. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) (Part1). Chin. J. Pract. Internal Med. 41(08), 668–695 (2021).
3. Fowler, M. J. Microvascular and macrovascular complications of diabetes. Clin. Diab. 26(2), 77–82 (2011).
4. Zhuo, X., Zhang, P. & Hoerger, T. J. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am. J. Prev. Med. 45(3), 253–261 (2013).
5. Goldhaber-Fiebert, J. D. et al. Inpatient treatment of diabetic patients in Asia: Evidence from India, China Thailand and Malaysia. Diabet. Med. 27(1), 101–108 (2010).